Shuaili Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Shuaili Xu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Chuanjie Wu
Xuanwu Hospital, Capital Medical University
2 shared publications - Di Wu
Department of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
2 shared publications - Xi Chen
Department of Neurology, China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publications - Xunming Ji
Capital Medical University
2 shared publications Baoying Song
Department of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing (Y.X., W.H., W.Z., C.W., Y.Z., S.X., B.S., X.J., D.W.).
1 shared publication- Chen Zhou
Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eady7847
The translational potential of drug-induced hypothermia in acute ischemic stroke
Hypothermia and hypometabolism are important for hibernating animals to survive harsh environmental conditions. Induction of a hypothermic and hypometabolic state is considered an avenue to treat severe diseases, such as ischemic stroke. However, noninvasive and safe methods to achieve a long-lasting hypothermic and hypometabolic state remain limited. Here, we present data from preclinical and clinical studies to explore the feasibility and safety of drug-induced hypothermia by administration of chlorpromazine and promethazine (C+P). In mice, C+P treatment induced hypothermia and suppressed glucose metabolism in the brain. C+P treatment reduced infarct volumes and improved neurological deficit in a mouse middle cerebral artery occlusion model induced by suture insertion. Furthermore, C+P treatment reduced body temperature, suppressed metabolism, and exerted cerebroprotective effects in a rhesus monkey model of stroke. In a double-blind, phase 1 clinical trial (NCT06663631), a total of 32 patients diagnosed with acute ischemic stroke were enrolled, receiving either placebo or increasing doses of C+P treatment: 10, 20, 50, or 100 milligrams. All doses were safe and well tolerated. Only 100 milligrams of C+P resulted in a modest and transient reduction in body temperature. Plasma proteomic profiling revealed a down-regulation of markers associated with aerobic respiration and glucose metabolism. These findings highlight the translational potential of C+P treatment and warrant a larger trial to further investigate safety and efficacy of C+P.
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eady7847
The translational potential of drug-induced hypothermia in acute ischemic stroke
Hypothermia and hypometabolism are important for hibernating animals to survive harsh environmental conditions. Induction of a hypothermic and hypometabolic state is considered an avenue to treat severe diseases, such as ischemic stroke. However, noninvasive and safe methods to achieve a long-lasting hypothermic and hypometabolic state remain limited. Here, we present data from preclinical and clinical studies to explore the feasibility and safety of drug-induced hypothermia by administration of chlorpromazine and promethazine (C+P). In mice, C+P treatment induced hypothermia and suppressed glucose metabolism in the brain. C+P treatment reduced infarct volumes and improved neurological deficit in a mouse middle cerebral artery occlusion model induced by suture insertion. Furthermore, C+P treatment reduced body temperature, suppressed metabolism, and exerted cerebroprotective effects in a rhesus monkey model of stroke. In a double-blind, phase 1 clinical trial (NCT06663631), a total of 32 patients diagnosed with acute ischemic stroke were enrolled, receiving either placebo or increasing doses of C+P treatment: 10, 20, 50, or 100 milligrams. All doses were safe and well tolerated. Only 100 milligrams of C+P resulted in a modest and transient reduction in body temperature. Plasma proteomic profiling revealed a down-regulation of markers associated with aerobic respiration and glucose metabolism. These findings highlight the translational potential of C+P treatment and warrant a larger trial to further investigate safety and efficacy of C+P.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 25 September 2024
- Published by Elsevier in Brain Research
- Vol. 1846, 149253
Remote ischemic conditioning slows blood-retinal barrier damage in type 1 diabetic rats
- 25 September 2024
- Published by Elsevier in Brain Research
- Vol. 1846, 149253
Remote ischemic conditioning slows blood-retinal barrier damage in type 1 diabetic rats
- Open Access
- 27 April 2020
- Published by Springer Nature in Hereditas
- Vol. 157 (1) , 1-15
Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility
The methylenetetrahydrofolate reductase (MTHFR) rs1801131 A/C variant results in a decrease in MTHFR enzymatic activity, which may play an important role in folate metabolism and is also an important source of DNA methylation and DNA synthesis. Several case-control studies have been conducted to assess the association of MTHFR rs1801131 polymorphism with the risk of urinary cancers, yet with conflicting conclusions. To derive a more precise estimation of above relationship, the association between the MTHFR rs1801131 A/C polymorphism and the risk of urinary cancer was performed. A total of 28 case-control studies was identified. The odds ratios (OR) with 95% confidence intervals (CI) was calculated to assess. On one hand, we found that the MTHFR rs1801131 A/C polymorphism was associated with increased whole urinary cancers’ risk (for example CA vs. AA: OR = 1.12. 95%CI = 1.01–1.24). On the other hand, we found that the MTHFR rs1801131 A/C polymorphism might increase bladder cancer risk both in Asian (C-allele vs. A-allele: OR = 1.35. 95%CI = 1.15–1.60) and African populations (CA vs. AA: OR = 1.63. 95%CI = 1.17–2.25). Our current analysis suggested that MTHFR rs1801131 A/C is associated with urinary cancers, especially bladder cancer.
- 27 April 2020
- Published by Springer Nature in Hereditas
- Vol. 157 (1) , 1-15
Open AccessAssociation between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors’ susceptibility
The methylenetetrahydrofolate reductase (MTHFR) rs1801131 A/C variant results in a decrease in MTHFR enzymatic activity, which may play an important role in folate metabolism and is also an important source of DNA methylation and DNA synthesis. Several case-control studies have been conducted to assess the association of MTHFR rs1801131 polymorphism with the risk of urinary cancers, yet with conflicting conclusions. To derive a more precise estimation of above relationship, the association between the MTHFR rs1801131 A/C polymorphism and the risk of urinary cancer was performed. A total of 28 case-control studies was identified. The odds ratios (OR) with 95% confidence intervals (CI) was calculated to assess. On one hand, we found that the MTHFR rs1801131 A/C polymorphism was associated with increased whole urinary cancers’ risk (for example CA vs. AA: OR = 1.12. 95%CI = 1.01–1.24). On the other hand, we found that the MTHFR rs1801131 A/C polymorphism might increase bladder cancer risk both in Asian (C-allele vs. A-allele: OR = 1.35. 95%CI = 1.15–1.60) and African populations (CA vs. AA: OR = 1.63. 95%CI = 1.17–2.25). Our current analysis suggested that MTHFR rs1801131 A/C is associated with urinary cancers, especially bladder cancer.